The Department of Medical Imaging is pleased to have Hongyun June Zhu, MD, DABR, presenting at our Grand Rounds on Thursday, August 16th, in the College of Medicine, Room 3117, at 12:00 pm.
Dr. Hongyun June Zhu is a Nuclear Medicine Physician with extensive experience in PET/CT and Nuclear Medicine. She was board certified by the American Board of Nuclear Medicine in 2008 after residency training at Emory University and board certified in Diagnostic Radiology by the American Board of Radiology in 2012. Dr. Zhu received her medical degree from the Suzhou University in Radiological Medical Science in 1993.
Dr. Zhu practiced eight years in both Diagnostic Radiology and Nuclear Medicine in China before she received an invitation from Stanford University School of Medicine in February 2001 and moved to the USA. She worked with Dr. Michael L. Goris, MD, PhD, as a post-doctoral research fellow in Nuclear Medicine and Radiation Oncology and participated in multiple programs at the interface of research and clinical practice before she completed a general surgery residency at Albert Einstein College of Medicine in 2006.
Dr. Zhu completed her nuclear medicine residency at Emory University in 2008. She fulfilled the American Board of Radiology training requirement and became board certified in Diagnostic Radiology in 2012. She served as a faculty member at the Department of Radiology, University of Arkansas for Medical Sciences since July 2008 for six years before she served as faculty member at the Department of Diagnostic Radiology, the University of Hong Kong July 2014 to July 2016. Dr. Zhu served as an attending physician at the Greater Los Angeles VA Hospital Department of Radiology, July 2016 to July 2017. She is currently a faculty member, a Clinical Associate Professor with pending rank at the Department of Diagnostic Radiology, Division of Nuclear Medicine at the University of Miami.
She has been actively involved in both clinical and research applications of conventional nuclear medicine as well as PET over the past two decades. Dr. Zhu has been actively involved in conducting research at Stanford, Emory, the University of Arkansas in Little Rock, the University of Hong Kong, and now the University of Miami.
Abstract: Multiple myeloma (MM) is one of the emerging indications and it illustrates many of the key features of using FDG-PET/CT in malignancies. It is the second most common hematological malignancy after Hodgkin’s lymphoma, and the most common primary bone marrow malignancy. In its classic form it presents as focal bony lesions, which are osteolytic in nature and associated with pathological fractures, extramedullary disease, and systemic immunodeficiency. Until recently, conventional radiographic methods, and to some extent MRI, have been employed as the mainstay of diagnostic imaging, but whole-body FDG-PET/CT is rapidly emerging as the modality of choice for assessing overall disease activity (skeletal and extramedullary), treatment planning (both initially, and for subsequent response assessment), follow up, and differentiating among different plasma cell dyscrasia subtypes. In addition, PET provides prognostic information which is not achievable from structural modalities.
College of Medicine, Room 3117